Patents by Inventor Dirk Heerding

Dirk Heerding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of AKT Activity
    Publication number: 20160287561
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: April 13, 2016
    Publication date: October 6, 2016
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • INHIBITORS OF Akt ACTIVITY
    Publication number: 20150152092
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: December 8, 2014
    Publication date: June 4, 2015
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • Inhibitors of AkT activity
    Patent number: 8946278
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Dennis S. Yamashita, Kenneth C. McNulty
  • Chemical compounds
    Patent number: 8598156
    Abstract: The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, and R3 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: December 3, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Jeffrey Michael Axten, Seth Wilson Grant, Dirk A. Heerding, Jesus Rual Medina, Stuart Paul Romeril, Jun Tang
  • INHIBITORS OF AkT ACTIVITY
    Publication number: 20130231378
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 5, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Mark A. SEEFELD, Meagan B. Rouse, Dirk A. Heerding, Dennis S. Yamashita, Kenneth C. McMulty
  • Inhibitors of Akt activity
    Patent number: 8410158
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: April 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • Deuterated benzene sulfonamide thiazole compounds
    Patent number: 8389723
    Abstract: Deuterated forms of N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and pharmaceutical compositions containing the same.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: March 5, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Jerry Leroy Adams, Dashyant Dhanak, Dirk A. Heerding, Calvin O. Manning
  • Deuterated Benzene Sulfonamide Thiazole Compounds
    Publication number: 20130053562
    Abstract: Deuterated forms of N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and pharmaceutical compositions containing the same.
    Type: Application
    Filed: July 26, 2012
    Publication date: February 28, 2013
    Inventors: Jerry Leroy Adams, Dashyant Dhanak, Dirk A. Heerding, Calvin O. Manning
  • CHEMICAL COMPOUNDS
    Publication number: 20130018038
    Abstract: The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, and R3 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: March 23, 2011
    Publication date: January 17, 2013
    Inventors: Jeffrey Michael Axten, Seth Wilson Grant, Dirk A. Heerding, Jesus Rual Medina, Stuart Paul Romeril, Jun Tang
  • Inhibitors of Akt activity
    Patent number: 8273782
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: September 25, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • CHEMICAL COMPOUNDS
    Publication number: 20120077828
    Abstract: The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, and R3 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: March 23, 2011
    Publication date: March 29, 2012
    Inventors: Jeffrey Michael Axten, Seth Wilson Grant, Dirk A. Heerding, Jesus Raul Medina, Stuart Paul Romeril, Jun Tang
  • Inhibitors of AKT Activity
    Publication number: 20110071182
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: December 23, 2008
    Publication date: March 24, 2011
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • INHIBITORS OF Akt ACTIVITY
    Publication number: 20100267759
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: February 7, 2008
    Publication date: October 21, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • INHIBITORS OF AKT ACTIVITY
    Publication number: 20100056523
    Abstract: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: November 9, 2006
    Publication date: March 4, 2010
    Inventors: Dirk A. Heerding, Tammy J. Clark, Jack Dale Leber, Igor Safonov
  • INHIBITORS OF Akt ACTIVITY
    Publication number: 20100041726
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: October 1, 2009
    Publication date: February 18, 2010
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
    Patent number: 7625890
    Abstract: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: December 1, 2009
    Assignee: SmithKline Beecham Corp.
    Inventors: Dirk A. Heerding, Tammy J. Clark, Jack Dale Leber, Igor Safonov
  • INHIBITORS OF AKT ACTIVITY
    Publication number: 20090227616
    Abstract: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: November 9, 2006
    Publication date: September 10, 2009
    Inventors: Dirk A. Heerding, Tammy J. Clark, Jack Dale Leber, Igor Safonov, Mie Li
  • INHIBITORS OF AKT ACTIVITY
    Publication number: 20090209607
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: February 7, 2008
    Publication date: August 20, 2009
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • Inhibitors of Akt Activity
    Publication number: 20080318947
    Abstract: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: April 20, 2006
    Publication date: December 25, 2008
    Inventors: Dirk A. Heerding, Meagan B. Rouse, Mark Andrew Seefeld
  • Inhibitors of Akt Activity
    Publication number: 20080269131
    Abstract: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: November 9, 2006
    Publication date: October 30, 2008
    Inventors: Dirk A. Heerding, Tammy J. Clark, Jack Dale Leber, Igor Safonov